2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T598,Dapsone (4,4'-Diamino diphenyl sulfone) has been utilized in managing a wide variety of mucocutaneous conditions, usually as a systemic product. Topical dapsone is commercially available as 5% and 7.5% gel and is FDA-approved for acne vulgaris. These topical formulations have shown less systemic absorption and fewer adverse events. Considering this, topical dapsone might benefit localized disease, immunosuppressed individuals, and those who avoid exposure to systemic therapies. Following PRISMA guidelines, a comprehensive literature search was conducted across PubMed, Web of Science, and Scopus databases for published papers up to April 2025. Then, eligible studies are included, and we summarize the findings of different clinical studies concerning the use, efficacy, and side effects of topical dapsone in various mucocutaneous conditions, excluding acne vulgaris. Finally, 56 articles were selected based on the eligibility criteria. We summarized and categorized them into two general entities, including applications of the topical dapsone and side effects of the topical dapsone. The first entity has six subheadings consisting of acne vulgaris and acneiform eruptions, Rosacea, neutrophilic dermatosis, vesiculobullous diseases, vasculitis, and others. In conclusion, topical dapsone appears to have therapeutic advantages in several mucocutaneous conditions, especially in minimal, localized, and chronic eruptions.31:T6da,ABSTRACTBackgroundDapsone (4,4′‐Diamino diphenyl sulfone) has been utilized in managing a wide variety of mucocutaneous conditions, usually as a systemic product. Topical dapsone is commercially available as 5% and 7.5% gel and is FDA‐approved for acne vulgaris. These topical formulations have shown less systemic absorption and fewer adverse events. Considering this, topical dapsone might benefit localized disease, immunosuppressed individuals, and those who avoid exposure to systemic therapies.MethodsFollowing PRISMA guidelines, a comprehensive literature search was conducted across PubMed, Web of Science, and Scopus databases for published papers up to April 2025. Then, eligible studies are included, and we summarize the findings of different clinical studies concerning the use, efficacy, and side effects of topical dapsone in various mucocutaneous conditions, excluding acne vulgaris.ResultsFinally, 56 articles were selected based on the eligibility criteria. We summarized and categorized them into two general entities, including applications of the topical dapsone and side effects of the topical dapsone. The first entity has six subheadings consisting of acne vulgaris and acneiform eruptions, Rosacea, neutrophilic dermatosis, vesiculobullous diseases, vasculitis, and others.ConclusionIn conclusion, topical dapsone appears to have therapeutic advantages in several mucocutaneous conditions, especially in minimal, localized, and chronic eruptions.25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Vasculitis: condition Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Vasculitis (condition). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/condition/Vasculitis\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Conditions\",\"item\":\"https://www.reachrx.ai/hub/tag/condition\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Vasculitis\",\"item\":\"https://www.reachrx.ai/hub/tag/condition/Vasculitis\"}]}}"}}]],["$","$L2f",null,{"title":"Vasculitis: Research & Clinical Takeaways","description":"Discover peer-reviewed research on Vasculitis with concise clinician summaries and next-step guidance.","papers":[{"doi":"10.18176/jiaci.1151","pmid":"41891507","title":"Acute Single Subcortical Infarction and Atypical Purpura in Eosinophilic Granulomatosis with Polyangiitis: A Case Report","journal_title":"Journal of Investigational Allergology and Clinical Immunology","journal_issn":"1018-9068","published_at":"2026-06-16T00:00:00.000Z","url":"https://doi.org/10.18176/jiaci.1151","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-22T13:24:16.722Z","updated_at":"2026-06-22T13:24:16.722Z","tags":[{"paper_doi":"10.18176/jiaci.1151","tag_type":"category","value":"Allergy","value_numeric":null},{"paper_doi":"10.18176/jiaci.1151","tag_type":"condition","value":"Acute Ischemic Stroke","value_numeric":null},{"paper_doi":"10.18176/jiaci.1151","tag_type":"condition","value":"Eosinophilic Granulomatosis with Polyangiitis","value_numeric":null},{"paper_doi":"10.18176/jiaci.1151","tag_type":"condition","value":"Purpura","value_numeric":null},{"paper_doi":"10.18176/jiaci.1151","tag_type":"condition","value":"Vasculitis","value_numeric":null},{"paper_doi":"10.18176/jiaci.1151","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.18176/jiaci.1151","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.18176/jiaci.1151","tag_type":"sample_size","value":"n=1","value_numeric":1},{"paper_doi":"10.18176/jiaci.1151","tag_type":"study_design","value":"Case Report","value_numeric":null},{"paper_doi":"10.18176/jiaci.1151","tag_type":"warning","value":"Age, sex, and treatment details of the patient are not available from the provided metadata alone; tags for age_group, sex, and modality/generic drug could not be populated.","value_numeric":null},{"paper_doi":"10.18176/jiaci.1151","tag_type":"warning","value":"The paper was published June 16, 2026, and is very recent — full text details (e.g., ANCA status, treatment used) were not supplied, so summary content is limited to what can be inferred from the title and journal entry.","value_numeric":null}],"summaries":{"what_studied":"A case report describing a patient with eosinophilic granulomatosis with polyangiitis (EGPA) who presented with two uncommon manifestations: acute single subcortical infarction (stroke) and atypical purpura.","key_result":"The case documents the co-occurrence of acute single subcortical cerebral infarction and atypical purpuric skin lesions as rare presenting features of EGPA, expanding the known clinical spectrum of this vasculitis.","limitations":"Single case report limits generalizability; causal mechanisms between EGPA and the neurological/cutaneous findings cannot be definitively established from one patient.","practice_takeaway":"Clinicians should consider EGPA in patients presenting with eosinophilia alongside atypical purpura or unexplained ischemic stroke, as neurological and atypical cutaneous manifestations may be underrecognized features of this vasculitis."}},{"doi":"10.1002/ijgo.71103","pmid":"42223974","title":"Rare vasculitis types and obstetric and neonatal outcomes – A population‐based study","journal_title":"International Journal of Gynecology & Obstetrics","journal_issn":"0020-7292","published_at":"2026-06-01T00:00:00.000Z","url":"https://doi.org/10.1002/ijgo.71103","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-10T14:23:55.399Z","updated_at":"2026-06-10T14:23:55.399Z","tags":[{"paper_doi":"10.1002/ijgo.71103","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1002/ijgo.71103","tag_type":"category","value":"Obstetrics & Gynecology","value_numeric":null},{"paper_doi":"10.1002/ijgo.71103","tag_type":"condition","value":"Giant Cell Arteritis","value_numeric":null},{"paper_doi":"10.1002/ijgo.71103","tag_type":"condition","value":"Hypertensive Disorders of Pregnancy","value_numeric":null},{"paper_doi":"10.1002/ijgo.71103","tag_type":"condition","value":"Kawasaki Disease","value_numeric":null},{"paper_doi":"10.1002/ijgo.71103","tag_type":"condition","value":"Polyarteritis Nodosa","value_numeric":null},{"paper_doi":"10.1002/ijgo.71103","tag_type":"condition","value":"Preterm Delivery","value_numeric":null},{"paper_doi":"10.1002/ijgo.71103","tag_type":"condition","value":"Takayasu Arteritis","value_numeric":null},{"paper_doi":"10.1002/ijgo.71103","tag_type":"condition","value":"Vasculitis","value_numeric":null},{"paper_doi":"10.1002/ijgo.71103","tag_type":"condition","value":"Wegener's Granulomatosis","value_numeric":null},{"paper_doi":"10.1002/ijgo.71103","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1002/ijgo.71103","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1002/ijgo.71103","tag_type":"sample_size","value":"n=9096788","value_numeric":9096788},{"paper_doi":"10.1002/ijgo.71103","tag_type":"sex","value":"female","value_numeric":null},{"paper_doi":"10.1002/ijgo.71103","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1002/ijgo.71103","tag_type":"warning","value":"ICD-9 coding is used for diagnosis; rare conditions may be under-coded or miscoded in administrative databases.","value_numeric":null},{"paper_doi":"10.1002/ijgo.71103","tag_type":"warning","value":"No information on vasculitis disease activity, flares during pregnancy, or specific immunosuppressive medications is available in the dataset, limiting causal inference.","value_numeric":null},{"paper_doi":"10.1002/ijgo.71103","tag_type":"warning","value":"The vasculitis group is very small (n=335 out of >9 million), so individual subtype-level analyses are not reported and estimates should be interpreted cautiously.","value_numeric":null}],"summaries":{"what_studied":"This retrospective cohort study used the HCUP-NIS database (2004–2014) to compare obstetric and perinatal outcomes in pregnant US women with rare vasculitis subtypes (polyarteritis nodosa, Kawasaki disease, hypersensitivity angiitis, Wegener's granulomatosis, giant cell arteritis, Takayasu arteritis) versus those without, among 9,096,788 deliveries.","key_result":"Only 335 women (3.7/100,000) had rare vasculitis. Compared to controls, they had significantly higher rates of hypertensive disorders of pregnancy (aOR 1.89), preterm delivery (aOR 1.76), blood transfusion (aOR 3.68), cesarean delivery (aOR 1.31), and congenital anomalies (aOR 4.1); placental abruption, hysterectomy, and VTE were comparable between groups.","limitations":"- Extremely small vasculitis group (n=335) limits statistical power and subgroup analysis by vasculitis type.\n- Retrospective ICD-9 coding may misclassify or undercount rare vasculitis diagnoses.\n- Database lacks disease activity, medication use (e.g., immunosuppressants), and disease severity data, which are key confounders.","practice_takeaway":"Pregnant women with rare vasculitis should be counseled about elevated risks of hypertensive disorders, preterm birth, cesarean delivery, and fetal congenital anomalies, and managed with close maternal-fetal medicine surveillance. Blood transfusion risk is notably high (aOR 3.68), warranting proactive hemorrhage planning."}},{"doi":"10.1038/s41584-026-01381-7","pmid":"42168623","title":"Treat-to-target in Behçet syndrome","journal_title":"Nature Reviews Rheumatology","journal_issn":"1759-4790","published_at":"2026-05-21T00:00:00.000Z","url":"https://doi.org/10.1038/s41584-026-01381-7","source_score":17,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-23T13:24:54.069Z","updated_at":"2026-05-23T13:24:54.069Z","tags":[{"paper_doi":"10.1038/s41584-026-01381-7","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1038/s41584-026-01381-7","tag_type":"category","value":"Rheumatology","value_numeric":null},{"paper_doi":"10.1038/s41584-026-01381-7","tag_type":"condition","value":"Behçet Syndrome","value_numeric":null},{"paper_doi":"10.1038/s41584-026-01381-7","tag_type":"condition","value":"Vasculitis","value_numeric":null},{"paper_doi":"10.1038/s41584-026-01381-7","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1038/s41584-026-01381-7","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1038/s41584-026-01381-7","tag_type":"modality","value":"Treat-to-Target Strategy","value_numeric":null},{"paper_doi":"10.1038/s41584-026-01381-7","tag_type":"study_design","value":"Expert Consensus / Perspective","value_numeric":null},{"paper_doi":"10.1038/s41584-026-01381-7","tag_type":"warning","value":"Impact flag 'practice_changing' is applied cautiously: the article proposes a novel T2T framework for a condition lacking one, but formal validation in prospective studies is still needed.","value_numeric":null},{"paper_doi":"10.1038/s41584-026-01381-7","tag_type":"warning","value":"No sample size is applicable — this is a Perspective/expert consensus article, not an interventional or observational study with enrolled patients.","value_numeric":null},{"paper_doi":"10.1038/s41584-026-01381-7","tag_type":"warning","value":"The study design label 'Expert Consensus / Perspective' is used because the paper does not fit a standard RCT, cohort, or systematic review design; level of evidence is assigned as 5 accordingly.","value_numeric":null}],"summaries":{"what_studied":"This expert consensus Perspective evaluates the treat-to-target (T2T) strategy in Behçet syndrome, proposing organ-based treatment goals, outcome measures, remission/relapse definitions, and monitoring strategies through multidisciplinary international collaboration.","key_result":"The authors propose an evidence-based T2T framework for Behçet syndrome covering major organ domains (ocular, neurological, gastrointestinal, vascular), with defined targets for remission and relapse and guidance on monitoring — filling a gap where formal T2T standards have not previously existed for this disease.","limitations":"The paper is a Perspective (expert opinion) rather than a clinical trial or systematic review, so its recommendations rest largely on indirect evidence and consensus rather than high-quality prospective data. The authors themselves acknowledge the limited literature on T2T specifically in Behçet syndrome.","practice_takeaway":"Clinicians managing Behçet syndrome should consider adopting an organ-specific T2T approach — defining clear remission targets and monitoring plans for each affected system — rather than relying solely on global disease activity assessments. This framework is intended to guide future trials and day-to-day clinical decision-making."}},{"doi":"10.1161/circresaha.125.327991","pmid":"42137941","title":"Sirtuin 1 Activation Mitigates Murine Vasculitis Severity by Promoting Mitophagy","journal_title":"Circulation Research","journal_issn":"0009-7330","published_at":"2026-05-15T00:00:00.000Z","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13182994/","source_score":13,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-26T13:25:33.842Z","updated_at":"2026-06-26T13:25:33.842Z","tags":[{"paper_doi":"10.1161/circresaha.125.327991","tag_type":"age_group","value":"pediatric","value_numeric":null},{"paper_doi":"10.1161/circresaha.125.327991","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1161/circresaha.125.327991","tag_type":"condition","value":"Coronary Artery Aneurysm","value_numeric":null},{"paper_doi":"10.1161/circresaha.125.327991","tag_type":"condition","value":"Kawasaki Disease","value_numeric":null},{"paper_doi":"10.1161/circresaha.125.327991","tag_type":"condition","value":"Vasculitis","value_numeric":null},{"paper_doi":"10.1161/circresaha.125.327991","tag_type":"generic","value":"nicotinamide","value_numeric":null},{"paper_doi":"10.1161/circresaha.125.327991","tag_type":"generic","value":"sirtuin 1","value_numeric":null},{"paper_doi":"10.1161/circresaha.125.327991","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1161/circresaha.125.327991","tag_type":"level_of_evidence","value":"6","value_numeric":null},{"paper_doi":"10.1161/circresaha.125.327991","tag_type":"modality","value":"NAD+ Precursor Supplementation","value_numeric":null},{"paper_doi":"10.1161/circresaha.125.327991","tag_type":"modality","value":"Sirtuin Activator","value_numeric":null},{"paper_doi":"10.1161/circresaha.125.327991","tag_type":"study_design","value":"Animal Study (Preclinical)","value_numeric":null},{"paper_doi":"10.1161/circresaha.125.327991","tag_type":"warning","value":"Sample sizes for individual mouse cohorts are not reported in the abstract; exact N is indeterminable from the provided text.","value_numeric":null},{"paper_doi":"10.1161/circresaha.125.327991","tag_type":"warning","value":"The paper is published in 2026 but the findings are mechanistic/animal-model based — impact flag set to 'limited_evidence' reflecting the preclinical nature rather than strength of the biology.","value_numeric":null},{"paper_doi":"10.1161/circresaha.125.327991","tag_type":"warning","value":"This is an entirely preclinical (murine) study; no human data are presented, so clinical applicability is speculative at this stage.","value_numeric":null}],"summaries":{"what_studied":"This study investigated the role of the NAD⁺–SIRT1 axis in Kawasaki disease vasculitis using the LCWE murine model, evaluating NAD⁺ precursor supplementation, SIRT1-overexpressing transgenic mice, and cell-specific Sirt1 knockout (vascular smooth muscle cells and myeloid cells) on vasculitis severity, cardiac function, immune infiltration, and mitophagy.","key_result":"SIRT1 expression was downregulated in cardiovascular lesions of LCWE-injected mice alongside reduced circulating nicotinamide. NAD⁺ precursor supplementation or SIRT1 overexpression significantly reduced vasculitis development and restored impaired ejection fraction, while Sirt1 deletion in vascular smooth muscle cells or myeloid cells worsened vasculitis. SIRT1 overexpression rescued impaired mitophagy/autophagy, reversed the pathogenic synthetic switch of vascular smooth muscle cells, and reduced proinflammatory cytokine production.","limitations":"Findings are entirely from a murine (LCWE) model; direct translation to human Kawasaki disease is unproven. The study does not test NAD⁺ precursor supplementation in humans or establish dosing relevant to clinical use. Mechanistic findings rely on transgenic overexpression, which may not reflect physiologically achievable SIRT1 levels.","practice_takeaway":"While not yet clinically actionable, these preclinical data suggest that boosting the NAD⁺–SIRT1 pathway (e.g., via NAD⁺ precursor supplementation) may be a future therapeutic strategy to reduce cardiovascular inflammation in Kawasaki disease. Clinicians should watch for translational trials targeting this axis in pediatric vasculitis."}},{"doi":"10.1111/jocd.70494","pmid":"41051026","title":"Efficacy and Safety of Topical Dapsone in Dermatology: A Scoping Review of Clinical Studies","journal_title":"Journal of Cosmetic Dermatology","journal_issn":"1473-2130","published_at":"2025-10-06T00:00:00.000Z","url":"https://doi.org/10.1111/jocd.70494","source_score":7,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2025-10-12","doi":"10.1111/jocd.70494","days":"7","issn":"1473-2130","rank":"9","field":"Clinical Medicine","score":"7","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1111/jocd.70494","title":"Efficacy and Safety of Topical Dapsone in Dermatology: A Scoping Review of Clinical Studies.","journal":"Journal of cosmetic dermatology","methods":"","results":"Finally, 56 articles were selected based on the eligibility criteria. We summarized and categorized them into two general entities, including applications of the topical dapsone and side effects of the topical dapsone. The first entity has six subheadings consisting of acne vulgaris and acneiform eruptions, Rosacea, neutrophilic dermatosis, vesiculobullous diseases, vasculitis, and others.","abstract":"$30","keywords":["dapsone","dermatology","skin","sulfones","topical"],"pubmed_id":"41051026","conclusions":"In conclusion, topical dapsone appears to have therapeutic advantages in several mucocutaneous conditions, especially in minimal, localized, and chronic eruptions.","publication_date":"2025-10-06T00:00:00"},"crossref":{"DOI":"10.1111/jocd.70494","URL":"https://doi.org/10.1111/jocd.70494","ISSN":["1473-2130","1473-2165"],"link":[{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/jocd.70494","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":"10","score":1,"title":["Efficacy and Safety of Topical Dapsone in Dermatology: A Scoping Review of Clinical Studies"],"author":[{"given":"Bahareh","family":"Abtahi‐Naeini","sequence":"first","affiliation":[{"name":"Pediatric Dermatology Division, Department of Pediatrics Imam Hossein Children's Hospital, Isfahan University of Medical Sciences Isfahan Iran"},{"name":"Skin Diseases and Leishmaniasis Research Center Isfahan University of Medical Sciences Isfahan Iran"}]},{"given":"Hossein","family":"Sattari","sequence":"additional","affiliation":[{"name":"Clinical Research Development Center, Najafabad Branch Islamic Azad University Najafabad Iran"},{"name":"Student Research Committee Isfahan University of Medical Sciences Isfahan Iran"}]},{"given":"Kimia","family":"Afshar","sequence":"additional","affiliation":[{"name":"Student Research Committee Isfahan University of Medical Sciences Isfahan Iran"}]},{"given":"Fereshte","family":"Rastegarnasab","sequence":"additional","affiliation":[{"name":"Student Research Committee Isfahan University of Medical Sciences Isfahan Iran"}]},{"given":"Mahsa","family":"Pourmahdi‐Boroujeni","sequence":"additional","affiliation":[{"name":"Student Research Committee Isfahan University of Medical Sciences Isfahan Iran"},{"name":"Isfahan Eye Research Center Isfahan University of Medical Sciences Isfahan Iran"}]}],"issued":{"date-parts":[[2025,10]]},"member":"311","prefix":"10.1111","source":"Crossref","volume":"24","archive":["Portico"],"created":{"date-time":"2025-10-06T23:34:06Z","timestamp":1759793646000,"date-parts":[[2025,10,6]]},"indexed":{"date-time":"2025-10-16T08:40:44Z","timestamp":1760604044979,"date-parts":[[2025,10,16]]},"license":[{"URL":"http://creativecommons.org/licenses/by/4.0/","start":{"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000,"date-parts":[[2025,10,6]]},"delay-in-days":5,"content-version":"vor"}],"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://onlinelibrary.wiley.com/doi/10.1111/jocd.70494"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2025-06-09"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2025-09-26"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2025-10-06"}],"deposited":{"date-time":"2025-10-16T08:15:38Z","timestamp":1760602538000,"date-parts":[[2025,10,16]]},"issn-type":[{"type":"print","value":"1473-2130"},{"type":"electronic","value":"1473-2165"}],"published":{"date-parts":[[2025,10]]},"publisher":"Wiley","reference":[{"DOI":"10.21037/apm-21-3935","key":"e_1_2_11_2_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1080/17425255.2019.1600670","key":"e_1_2_11_3_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s00403-013-1409-7","key":"e_1_2_11_4_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/ijd.14761","key":"e_1_2_11_5_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1080/15569527.2021.2024565","key":"e_1_2_11_6_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1177/1203475416651053","key":"e_1_2_11_7_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/ipd.12615","key":"e_1_2_11_8_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_11_9_1","year":"2012","issue":"4","author":"Handler M. Z.","volume":"6","first-page":"132","unstructured":null,"article-title":"Letter to the Editor: Application of Dapsone 5% Gel in a Patient With Dermatitis Herpetiformis","journal-title":"Journal of Dermatology Case Reports","doi-asserted-by":null},{"DOI":"10.1177/1203475418795818","key":"e_1_2_11_10_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_11_11_1","year":"2011","issue":"9","author":"Handler M. Z.","volume":"10","first-page":"1059","unstructured":null,"article-title":"Treatment of Peristomal Pyoderma Gangrenosum With Topical Crushed Dapsone","journal-title":"Journal of Drugs in Dermatology","doi-asserted-by":null},{"DOI":"10.1177/1203475418782140","key":"e_1_2_11_12_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/pde.13471","key":"e_1_2_11_13_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/1346-8138.14953","key":"e_1_2_11_14_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2011.10.011","key":"e_1_2_11_15_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2021.07.004","key":"e_1_2_11_16_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.4103/ijt.ijt_39_22","key":"e_1_2_11_17_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.4103/ds.DS-D-24-00037","key":"e_1_2_11_18_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_11_19_1","year":"2013","issue":"4","author":"Frieling G. W.","volume":"12","first-page":"481","unstructured":null,"article-title":"Novel Use of Topical Dapsone 5% Gel for Erythema Elevatum Diutinum: Safer and Effective","journal-title":"Journal of Drugs in Dermatology","doi-asserted-by":null},{"DOI":null,"key":"e_1_2_11_20_1","year":"2017","issue":"6","author":"Pate D. A.","volume":"99","first-page":"426","unstructured":null,"article-title":"Leukocytoclastic Vasculitis Resolution With Topical Dapsone","journal-title":"Cutis","doi-asserted-by":null},{"DOI":null,"key":"e_1_2_11_21_1","year":"2016","issue":"4","author":"Aflatoonian M.","volume":"26","first-page":"353","unstructured":null,"article-title":"The Efficacy of Combined Topical Niosomal Dapsone Gel and Intralesional Injection of Meglumine Antimoniate in Comparison With Intralesional Meglumine Antimoniate and Cryotherapy in the Treatment of Cutaneous Leishmaniasis","journal-title":"Journal of Pakistan Association of Dermatologists","doi-asserted-by":null},{"DOI":null,"key":"e_1_2_11_22_1","year":"2015","issue":"6","author":"Faghihi G.","volume":"14","first-page":"602","unstructured":null,"article-title":"Dapsone Gel in the Treatment of Papulopustular Rosacea: A Double‐Blind Randomized Clinical Trial","journal-title":"Journal of Drugs in Dermatology","doi-asserted-by":null},{"DOI":"10.1080/15569527.2024.2424932","key":"e_1_2_11_23_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/ced.13742","key":"e_1_2_11_24_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_11_25_1","year":"2024","issue":"1","author":"Gökşin Ş.","volume":"14","first-page":"1","unstructured":null,"article-title":"Efficacy of Topical Dapsone 5% Gel for the Treatment of Erythematotelangiectatic Rosacea: New Treatment Option With Old Drug","journal-title":"Dermatology Practical & Conceptual","doi-asserted-by":null},{"DOI":"10.1159/000431171","key":"e_1_2_11_26_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.5070/D3208023535","key":"e_1_2_11_27_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_11_28_1","year":"2015","issue":"7","author":"Kassardjian M.","volume":"8","first-page":"48","unstructured":null,"article-title":"Management of Periocular Granuloma Annulare Using Topical Dapsone","journal-title":"Journal of Clinical and Aesthetic Dermatology","doi-asserted-by":null},{"DOI":null,"key":"e_1_2_11_29_1","year":"2015","issue":"5","author":"Watton C.","volume":"372","first-page":"492","unstructured":null,"article-title":"Methemoglobinemia as a Complication of Topical Dapsone","journal-title":"New England Journal of Medicine","doi-asserted-by":null},{"DOI":"10.1542/peds.2015-3186","key":"e_1_2_11_30_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/pde.14080","key":"e_1_2_11_31_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_11_32_1","year":"2022","issue":"9","author":"Cantrell C.","volume":"14","first-page":null,"unstructured":null,"article-title":"Refractory Methemoglobinemia Secondary to Topical Dapsone With Subsequent Autoimmune Hemolytic Anemia","journal-title":"Cureus Journal of Medical Science","doi-asserted-by":null},{"DOI":null,"key":"e_1_2_11_33_1","year":"2015","issue":"1","author":"Del Rosso J. Q.","volume":"8","first-page":"31","unstructured":null,"article-title":"Comparative Efficacy and Tolerability of Dapsone 5% Gel in Adult Versus Adolescent Females With Acne Vulgaris","journal-title":"Journal of Clinical and Aesthetic Dermatology","doi-asserted-by":null},{"DOI":"10.1016/j.jaad.2006.10.005","key":"e_1_2_11_34_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"}],"short-title":[],"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"update-policy":"https://doi.org/10.1002/crossmark_policy","alternative-id":["10.1111/jocd.70494"],"article-number":"e70494","content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Journal of Cosmetic Dermatology"],"published-print":{"date-parts":[[2025,10]]},"reference-count":33,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,10,6]]},"references-count":33,"short-container-title":["J of Cosmetic Dermatology"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1111/jocd.70494","is_oa":true,"title":"Efficacy and Safety of Topical Dapsone in Dermatology: A Scoping Review of Clinical Studies","updated":"2025-10-11T00:07:04+00:00","published_date":"2025-10-01","best_oa_location":{"url":"https://doi.org/10.1111/jocd.70494","pmh_id":null,"url_for_pdf":null,"url_for_landing_page":"https://doi.org/10.1111/jocd.70494"}}},"created_at":"2025-10-16T07:50:39.785Z","updated_at":"2025-10-18T07:47:19.581Z","tags":[{"paper_doi":"10.1111/jocd.70494","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1111/jocd.70494","tag_type":"condition","value":"Acne Vulgaris","value_numeric":null},{"paper_doi":"10.1111/jocd.70494","tag_type":"condition","value":"Neutrophilic Dermatoses","value_numeric":null},{"paper_doi":"10.1111/jocd.70494","tag_type":"condition","value":"Rosacea","value_numeric":null},{"paper_doi":"10.1111/jocd.70494","tag_type":"condition","value":"Vasculitis","value_numeric":null},{"paper_doi":"10.1111/jocd.70494","tag_type":"condition","value":"Vesiculobullous Diseases","value_numeric":null},{"paper_doi":"10.1111/jocd.70494","tag_type":"generic","value":"dapsone","value_numeric":null},{"paper_doi":"10.1111/jocd.70494","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1111/jocd.70494","tag_type":"modality","value":"Topical Sulfone","value_numeric":null},{"paper_doi":"10.1111/jocd.70494","tag_type":"sample_size","value":"n=56","value_numeric":56},{"paper_doi":"10.1111/jocd.70494","tag_type":"study_design","value":"Scoping Review","value_numeric":null},{"paper_doi":"10.1111/jocd.70494","tag_type":"warning","value":"Heterogeneous conditions and designs make the study type classification and generalizability uncertain.","value_numeric":null},{"paper_doi":"10.1111/jocd.70494","tag_type":"warning","value":"Only abstract-level details are available; no pooled or numeric outcomes were reported here.","value_numeric":null},{"paper_doi":"10.1111/jocd.70494","tag_type":"warning","value":"The abstract is inconsistent about excluding versus including acne vulgaris.","value_numeric":null}],"summaries":{"what_studied":"A PRISMA-guided scoping review searched PubMed, Web of Science, and Scopus through April 2025 and included 56 clinical articles on topical dapsone (5% or 7.5% gel) for mucocutaneous conditions, summarizing efficacy and side effects.","limitations":"The evidence is a scoping review across diverse conditions without quantified outcomes. The abstract conflicts on whether acne vulgaris was excluded or included.","practice_takeaway":"Topical dapsone (5% or 7.5% gel) may be an option for localized, chronic mucocutaneous eruptions when avoiding systemic therapy, but the support is heterogeneous and not quantified here."}}],"initialOffset":5,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"condition","value":"Vasculitis"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Conditions","href":"/hub/tag/condition"},{"name":"Vasculitis"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"condition","hub_tag_value":"Vasculitis"}}}]]

Papers